Search results
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
Zacks via Yahoo Finance· 6 months agoRegeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced positive study data on the...
Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal
Zacks via Yahoo Finance· 2 years agoSanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase...
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
Benzinga via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Phase 3 trial of Dupixent...
Pharma Stock Roundup: MRK Buys Cancer Drug Rights, SNY Dupixent Kids Study Succeeds
Zacks via Yahoo Finance· 2 years agoThis week, Merck MRK in-licensed co-development rights to Orion Corporation’s prostate cancer...
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
Zacks via Yahoo Finance· 4 months agoThe FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include...
Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent
Zacks via Yahoo Finance· 2 years agoRegeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug...
Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers
Investor's Business Daily· 7 months agoRegeneron Pharmaceuticals' high-dose Eylea is off to a strong start in the U.S., the company said...
US FDA approves Dupixent to treat younger kids with esophageal condition
Reuters via Yahoo News· 4 months ago(Reuters) -The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to...
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
Zacks via Yahoo Finance· 1 year agoThis week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a...
Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product
Benzinga via Yahoo Finance· 2 years agoSanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) presented more positive...